ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RCKT vs BIOA // ALTMAN Z-SCORE & DEBT/EQUITY

Rocket Pharmaceuticals Inc. (NASDAQ) VS. BioAge Labs Inc. (NASDAQ) • 15-METRIC TALLY: RCKT 3 — BIOA 1
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: BIOA
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCKT VS. BIOA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RCKT BIOA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE 0.20 5.66 -5.46 BIOA /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 RCKT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.2 43.4 +1.87 RCKT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $278.8M $272.6M $6.2M RCKT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RCKT REV BIOA REV RCKT GROSS % BIOA GROSS % RCKT FCF BIOA FCF
FY 2025 $0 $9.0M — — -$190.5M -$82.3M
FY 2024 $0 $0 — — -$215.6M -$51.9M
FY 2023 $0 $0 — — -$194.9M -$37.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCKT // BETA —
BIOA // BETA —